Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-09-08
2011-10-11
Desai, Anand (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C536S023100
Reexamination Certificate
active
08034764
ABSTRACT:
A method is provided for treating conditions that are susceptible of treatment with a cytokine wherein certain physiological processes normally associated with cytokine administration (e.g. the induction of SOCS 1 and/or SOCS 3) are diminished or eliminated. The method comprises continuously administering a controlled dose of a cytokine to an individual afflicted with a condition susceptible of treatment with the cytokine.
REFERENCES:
patent: 6041788 (2000-03-01), Shen
patent: 6461605 (2002-10-01), Cutler et al.
patent: 6575169 (2003-06-01), McMichael
patent: 2003/0191058 (2003-10-01), Nicholson et al.
patent: WO 97/44057 (1997-11-01), None
patent: WO 2004/078127 (2004-09-01), None
patent: WO 2004/078193 (2004-09-01), None
patent: WO 2004/078194 (2004-09-01), None
patent: WO 2004/078207 (2004-09-01), None
Hebenstreit et al., Journal of Immunology 171: 5901-5907 (Sep. 2003), “IL-4 and IL-13 induce SOCS-1 gene expression in A549 cells by three functional STAT6-binding motifs located upstream of the transcription intiation site”.
W.S. Alexander et al., “Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction,” 1999, J. Leukocyte Biology, 66(4):588-592.
J.G. Bode et al., “IFN-α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-31,” Mar. 2003, The FASEB Journal, 17:488-490.
J. Chen et al., “Stat5 is a physiological substrate of the insulin receptor,” Mar. 1997, Proc. Natl. Acad. Sci. USA, 94:2295-2300.
X.P. Chen et al., “SOCS proteins, regulators of intracellular signaling,” Sep. 2000, Immunity, 13(3):287-290.
M.M.W. Chong et al, “γ-Interferon Signaling in Pancreatic β-Cells Is Persistent but Can Be Terminated by Overexpression of Suppressor of Cytokine Signaling-1,” Dec. 2001, Diabetes, 50:2744-2751.
A.L. Cornish et al., “Suppressor of Cytokine Signaling-1 Has IFN-γ-Independent Actions in T Cell Homeostasis1,” 2003, The Journal of Immunology, 170:878-886.
S. Cottet et al., “SOCS-1 Protein Prevents Janus Kinase/STAT-dependent Inhibition of β Cell Insulin Gene Transcription and Secretion in Response to Interferon-γ,” Jul. 13, 2001, J. Bio Chem, 276(28): 25862-25870.
A. Crespo et al., “Low responsiveness to IFN-γ, after pretreatment of mouse macrophages with lipopolysaccharides, develops via diverse regulatory pathways,” 2002, Eur. J. Immunol, 32:710-719.
H.L. Dickensheets et al., “Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducingSOCS-1gene expression,” Sep. 1999, Proc. Natl. Acad. Sci. USA, 96:10800-10805.
B. Emanuelli et al., “SOCS-3 is an insulin-induced negative regulator of insulin signaling,” May 2000, J Biol Chem., 275(21):15985-15991.
B. Emanuelli et al., “SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice,” Dec. 2001, J Biol Chem., 276(51):47944-47949.
M. Federici et al., “Impaired IFN-γ-Dependent Inflammatory Responses in Human Keratinocytes Overexpressing the Suppressor of Cytokine Signaling 11,” 2002, The Journal of Immunology,.168:434-442.
K. Friederichs et al., “Interleukin-6-induced proliferation of pre-B cells mediated by receptor complexes lacking the SHP2/SOCS3 recruitment sites revisited,” Dec. 2001, Eur J Biochem., 268(24):6401-6407.
M. Fujimoto et al., “A regulatory role for suppressor of cytokine signaling-1 in Th, polarization in vivo,” 2002, International Immunology, 14(11):1343-1350.
M. Gadina et al., “Signaling by type I and II cytokine receptors: ten years after,” Jun. 2001, Curr Opin Immunol., 13(3):363-373.
X. Hu et al., “Sensitization of IFN-γ Jak-STAT signaling during macrophage activation,” Sep. 2002, Nature Immunology, 3(9):859-866.
Y. Kawazoe et al., “Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (TRS-1) phosphorylation,” Jan. 2001, J Exp Med. 193(2):263-269.
M.N. Le et al., “Dual mechanism of signal transducer and activator of transcription 5 activation by the insulin receptor,” Dec. 2002, Mol Endocrinol.,16(12):2764-2779.
J.A. Losman et al., “Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction,” Apr. 1999, J Immunol., 162(7):3770-3774.
R.A. Mooney et al., “Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance,” Jul. 2001, J Biol Chem., 276(28):25889-25893.
Y. Morita et al., “Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts,” May 2000, Proc Natl Acad Sci U S A., 97(10):5405-5410.
N. A. Nicola, “The suppressors of cytokine signaling (SOCS): proteins: Important feedback inhibitors of cytokine action,” 2000, Experimental Hematology, 28:1105-1112.
G.M. O'Keefe et al., “IFN-γ Regulation of Class II Transactivator Promoter IV in Macrophages and Microglia: Involvement of the Suppressors of Cytokine Signaling-1 Protein,” 2001, The Journal of Immunology, 166:2260-2269.
P. Peraldi et al., “Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase.,” Jul. 2001, J. Biol. Chem., 276(27):24614-24620.
S.G. Ronn et al., “The effect of suppressor of cytokine signaling 3 on GH signaling in beta-cells,” Sep. 2002, Mol Endocrinol., 16(9):2124-2134.
C.L Sadowski et al., “Insulin Induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 Skeletal Muscle Cells Is Mediated by Stat5,”Jun. 2001, J Biol Chem., 276(23):20703-20710.
H. Sakamoto et al., “AJanusKinase Inhibitor, JAB, Is an Interferon-γ-Inducible Gene and Confers Resistance to Interferons,” 1998, Blood, 92(5):1668-1676.
J.W. Slaton et al., “Interferon-α-mediated Down-Regulation of Angiogenesis-related Genes and Therapy of Bladder Cancer Are Dependent on Optimization of Biological Dose and Schedule1,” Oct. 1999, Clinical Cancer Research, 5:2726-2734.
M.M. Song et al., “The Suppressor of Cytokine Signaling (SOCS) 1 and SOCS3 but Not SOCS2 Proteins Inhibit Inteferon-mediated Antiviral and Antiproliferative Activities,” Dec. 1998, J. Biol Chem., 273(52):35056-35062.
B. Sporri et al., “JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling,” Jan. 2001, Blood, 97(1):221-226.
G.R. Stark et al., “How cells respond to interferons,”1998, Annu Rev Biochem., 67:227-264.
R. Starr et al., “A family of cytokine-inducible inhibitors of signalling,” Jun. 1997, Nature, 387(6636):917-921.
S. Trop et al., “Overexpression of suppressor of cytokine signaling-1 impairs pre-T-cell receptor-induced proliferation but not differentiation of immature thymocytes,” Apr. 2001, Blood, 97(8):2269-2277.
D.R. Wesemann et al., “Suppressor of Cytokine Signaling 1 Inhibits Cytokine Induction of CD40 Expression in Macrophages1,” 2002, The Journal of Immunology, 169:2354-2360.
H. Yasukawa et al., “Negative Regulation of Cytokine Signaling Pathways,” 2000, Annu. Rev. Immunol., 18:143-164.
Tsunoo, H., et al., “Effects of Inerferon-β in combination with 5-Fluorouracil on the Growth of Esophageal Cancer Cells In Vitor”, Anticancer Research 21:3301-3306 (2001).
Sakai, I., et al., “Constitutive expressionof SOCS3 confers resistance to IFN-α in chronic myelogenous leukemia cells”, The American Society of Hematology, vol. 100, No. 8, Oct. 15, 2002, XP-
Gulati Poonam S.
Van Antwerp William P.
Desai Anand
Gates & Cooper LLP
Medtronic MiniMed, Inc.
LandOfFree
Modulation of SOCS expression in therapeutic regimens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of SOCS expression in therapeutic regimens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of SOCS expression in therapeutic regimens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4291893